Cargando…
Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure
AIMS: To explore the associations between serum phenylacetylglutamine (PAGln) and chronic heart failure (HF). METHODS AND RESULTS: Totally 956 subjects were enrolled consecutively from the Department of Cardiovascular Medicine, Ruijin Hospital. Baseline data were obtained from all participants, and...
Autores principales: | Zong, Xiao, Fan, Qin, Yang, Qian, Pan, Roubai, Zhuang, Lingfang, Tao, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288759/ https://www.ncbi.nlm.nih.gov/pubmed/35624536 http://dx.doi.org/10.1002/ehf2.13989 |
Ejemplares similares
-
Trimethyllysine, a trimethylamine N-oxide precursor, predicts the presence, severity, and prognosis of heart failure
por: Zong, Xiao, et al.
Publicado: (2022) -
PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway
por: Yang, Qian, et al.
Publicado: (2023) -
Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
por: Zhang, Zhendong, et al.
Publicado: (2023) -
Urine Phenylacetylglutamine Determination in Patients with Hyperphenylalaninemia
por: Andrade, Fernando, et al.
Publicado: (2021) -
Phenylacetylglutamine, a Novel Biomarker in Acute Ischemic Stroke
por: Yu, Fang, et al.
Publicado: (2021)